We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Read MoreHide Full Article
Key Takeaways
The study showed Pyrukynd met its hemoglobin endpoint but missed its goal of reducing pain crises.
AGIO reported mixed secondary results, with gains in hemoglobin and bilirubin but no fatigue improvement.
Agios plans a regulatory filing in early 2026, citing clearer benefits in hemoglobin responders.
Shares of Agios Pharmaceuticals (AGIO - Free Report) tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) in patients aged 16 years or older with sickle cell disease (SCD).
While the study did meet its primary endpoint of improving patients’ hemoglobin levels, it failed to achieve the other co-primary endpoint of reducing the annualized rate of sickle cell pain crises (SCPCs).
More on AGIO’s RISE UP Study Results
In terms of efficacy, data from the study showed that nearly 41% of Pyrukynd-treated patients achieved a hemoglobin response compared with around 3% in the placebo arm. While patients treated with the drug did show numerical reductions in SCPCs — 2.62 for Pyrukynd-treated vs. 3.05 for placebo — it failed to achieve statistical significance and therefore did not meet this co-primary endpoint.
The results were also mixed across the key secondary endpoints. While Pyrukynd-treated patients showed statistically significant improvements in average hemoglobin concentration and indirect bilirubin levels, it fell short in improving patient-reported fatigue.
Despite the mixed results, Agios is preparing to move forward with a regulatory filing for the drug. It emphasizes findings from a post hoc analysis of hemoglobin responders, a subgroup of SCD patients that not only achieved the primary endpoint but also showed clearer clinical benefits, including reduced SCPCs and improved patient-reported fatigue. The company intends to submit this regulatory filing after meeting with the FDA in the first quarter of 2026.
An oral pyruvate kinase (PK) activator, Pyrukynd is currently approved in the United States and Europe for treating hemolytic anemia in adults with PK deficiency. A regulatory filing is currently under FDA review, seeking label expansion for the drug across both alpha- or beta-thalassemia patients who are non-transfusion-dependent (NTD) and transfusion-dependent (TD), respectively. A final decision is expected by Dec. 7, 2025.
AGIO Stock’s Performance
Following the mixed study results, shares of Agios hit a 52-week low of $22.24. The latest announcement failed to impress investors, who had high hopes for Pyrukynd to meet both study goals. Some investors also questioned the drug’s future in SCD — an area with significant commercial potential that the company was planning to enter next year.
Year to date, the company’s shares have lost 32% against the industry’s 17% growth.
Image Source: Zacks Investment Research
Rival Fulcrum Shares Gains on Agios’ Setback
Post the results announcement, shares of clinical-stage biotech Fulcrum Therapeutics (FULC - Free Report) gained over 18% in one trading session. FULC is developing an investigational drug called pociredir, which is currently being evaluated in an early-stage study for SCD.
Wall Street expressed optimism around the Fulcrum Therapeutics drug, which utilizes a different mechanism to treat SCD.
Earnings per share (EPS) estimates for Alkermes’ 2025 have increased from $1.82 to $1.96, while those for 2026 have risen from $1.59 to $1.66 in the past 60 days. ALKS stock has registered breakeven growth year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s EPS have increased from $1.24 to $2.87 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.88. Year to date, shares of CRMD have rallied 24%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.04%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results
Key Takeaways
Shares of Agios Pharmaceuticals (AGIO - Free Report) tanked about 51% on Wednesday after it reported mixed top-line results from the phase III RISE UP study, which evaluated orally administered Pyrukynd (mitapivat) in patients aged 16 years or older with sickle cell disease (SCD).
While the study did meet its primary endpoint of improving patients’ hemoglobin levels, it failed to achieve the other co-primary endpoint of reducing the annualized rate of sickle cell pain crises (SCPCs).
More on AGIO’s RISE UP Study Results
In terms of efficacy, data from the study showed that nearly 41% of Pyrukynd-treated patients achieved a hemoglobin response compared with around 3% in the placebo arm. While patients treated with the drug did show numerical reductions in SCPCs — 2.62 for Pyrukynd-treated vs. 3.05 for placebo — it failed to achieve statistical significance and therefore did not meet this co-primary endpoint.
The results were also mixed across the key secondary endpoints. While Pyrukynd-treated patients showed statistically significant improvements in average hemoglobin concentration and indirect bilirubin levels, it fell short in improving patient-reported fatigue.
Despite the mixed results, Agios is preparing to move forward with a regulatory filing for the drug. It emphasizes findings from a post hoc analysis of hemoglobin responders, a subgroup of SCD patients that not only achieved the primary endpoint but also showed clearer clinical benefits, including reduced SCPCs and improved patient-reported fatigue. The company intends to submit this regulatory filing after meeting with the FDA in the first quarter of 2026.
An oral pyruvate kinase (PK) activator, Pyrukynd is currently approved in the United States and Europe for treating hemolytic anemia in adults with PK deficiency. A regulatory filing is currently under FDA review, seeking label expansion for the drug across both alpha- or beta-thalassemia patients who are non-transfusion-dependent (NTD) and transfusion-dependent (TD), respectively. A final decision is expected by Dec. 7, 2025.
AGIO Stock’s Performance
Following the mixed study results, shares of Agios hit a 52-week low of $22.24. The latest announcement failed to impress investors, who had high hopes for Pyrukynd to meet both study goals. Some investors also questioned the drug’s future in SCD — an area with significant commercial potential that the company was planning to enter next year.
Year to date, the company’s shares have lost 32% against the industry’s 17% growth.
Image Source: Zacks Investment Research
Rival Fulcrum Shares Gains on Agios’ Setback
Post the results announcement, shares of clinical-stage biotech Fulcrum Therapeutics (FULC - Free Report) gained over 18% in one trading session. FULC is developing an investigational drug called pociredir, which is currently being evaluated in an early-stage study for SCD.
Wall Street expressed optimism around the Fulcrum Therapeutics drug, which utilizes a different mechanism to treat SCD.
AGIO’s Zacks Rank
Agios currently carries a Zacks Rank #3 (Hold).
Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote
Our Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are Alkermes (ALKS - Free Report) and CorMedix (CRMD - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Earnings per share (EPS) estimates for Alkermes’ 2025 have increased from $1.82 to $1.96, while those for 2026 have risen from $1.59 to $1.66 in the past 60 days. ALKS stock has registered breakeven growth year to date.
Alkermes’ earnings beat estimates in three of the trailing four quarters and missed the mark on one occasion, delivering an average negative surprise of 4.58%.
In the past 60 days, estimates for CorMedix’s EPS have increased from $1.24 to $2.87 for 2025. During the same time, EPS estimates for 2026 have increased from $2.09 to $2.88. Year to date, shares of CRMD have rallied 24%.
CorMedix’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.04%.